Boston-based pharmaceutical company Ratio Therapeutics has entered a long-term, multi-isotope supply agreement with Nusano to boost production of its cancer radiopharmaceuticals.
Under the agreement, Nusano will supply Ratio with copper-64 for developing PET imaging agents and lutetium-177 and actinium-225 for developing targeted therapies. Both companies have production facilities miles apart in Utah’s Salt Lake Valley, which will streamline the logistics involved in scale-up and delivery, Ratio said.
Ratio’s product pipeline includes a fibroblast activation protein (FAP)-targeted PET radiotracer for imaging soft tissue sarcoma, which is expected to enter the clinic this year, the company said.
